Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Open accessThe DOI matches its Crossref record; 17 of the 20 references it cites were found in a registry or an index; none of the 9 sources its claims cite is checked for support yet.
Abstract
Two Norwegian patients with chronic tyrosinemia type I showed > 50% residual fumarylacetoacetase activity in liver samples obtained during liver transplantation. The enzyme characteristics of both patients were comparable with those of a normal control. Immunohistochemistry on liver sections from these patients and from three other Norwegian tyrosinemia patients revealed a mosaicism of fumarylacetoacetase immunoreactivity corresponding completely or partly to some of the regenerating nodules. This appearance of enzyme protein is presumably induced by the disease process. The mechanism involved remains unclear and could be caused by a genetic alteration, regained translation of messenger RNA, or to enhanced stability of an abnormal enzyme.
Overview
CoChat Summary
## TL;DR
This study reports unexpected residual fumarylacetoacetase (FAH) activity and mosaic FAH immunoreactivity in liver tissue from patients with hereditary tyrosinemia type I, suggesting self-induced correction of the enzyme defect in some hepatocyte clones. The authors argue that this mosaicism could make liver-biopsy-based diagnosis misleading in chronic cases.
## Key findings
- In two Norwegian patients with chronic tyrosinemia type I, frozen liver samples taken at transplantation showed substantial FAH activity: patient 1 had 6–32 U/g protein and patient 2 had 26 U/g protein, compared with 33–66 U/g protein in controls.
- Immunohistochemistry showed a mosaic pattern of FAH staining in regenerating nodules; in patient 2, one section showed FAH immunoreactivity in only two regenerating nodules, while another section from the same patient showed all nodules positive.
- Similar mosaic FAH staining was seen in the other studied tyrosinemia patients, including patient 4, and the authors state mosaicism was observed in patients 1, 3, and 5 as well.
- The FAH enzyme from patients 1 and 2 had Km, Vmax, pH optimum, inhibition pattern toward metal ions, and freeze/thaw stability comparable with a normal control, supporting the idea that the reexpressed enzyme was functionally normal.
## Methods
- The study examined five Norwegian tyrosinemia type I patients diagnosed at 1–6 years of age by low FAH activity in fibroblasts and/or lymphocytes plus elevated urinary succinylacetone.
- Liver tissue collected at transplantation was analyzed by FAH activity assays, Western blotting, subcellular fractionation (patient 2), and immunohistochemistry using the APAAP method on formalin-fixed paraffin-embedded sections.
- The authors compared enzyme kinetics and inhibitor sensitivity in patients 1 and 2 with a normal control, and also examined liver sections from normal controls and patients with cirrhosis from other causes.
## Limitations
- The paper does not identify the mechanism of correction; it explicitly says the mechanism remains unclear and could involve a genetic alteration, regained translation of mRNA, or enhanced stability of an abnormal enzyme.
- The findings are based on a small sample of five patients, with detailed biochemical characterization concentrated in two patients.
- Evident from the text: the study is observational and cannot determine causality for the mosaicism or prove which proposed mechanism is correct.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 1 Not valid · 6 Not checked · 18 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two Norwegian patients with chronic tyrosinemia type I showed > 50% residual fumarylacetoacetase activity in liver samples obtained during liver transplantation.”
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The three cirrhotic patients with either chronic active hepatitis (Fig. 4) or chronic autoimmune hepatitis had immunoreactive FAH protein in all regenerating nodules.”
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no apparent morphological difference between positive and negative hepatocytes (C and D) in this patient.”
hedgedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunohistochemistry on liver sections from these patients and from three other Norwegian tyrosinemia patients revealed a mosaicism of fumarylacetoacetase immunoreactivity corresponding completely or partly to some of the regenerating nodules.”
- Also stated in: § Results · plain
“a distinct mosaic pattern of FAH with immunoreactivity confined to only two regeneration nodules was seen in one section (A), whereas in another section (B), all nodules were positive.”
- Also stated in: § Results · plain
“Mosaicism was observed also in the other three patients (1, 3, and 5); some sections showed mostly immunoreactive nodules while other areas were mainly negative.”
plainstates an associationn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The enzyme characteristics of both patients were comparable with those of a normal control.”
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 25 claims and every source verdict.
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 4
- It may state two separate claims as one. 6
Citations
Cites
Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue
de Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R., & Appelmans, F. (1955) · Biochemical Journal · doi:10.1042/bj0600604 · Cited by 4,174
Review and hypotheses: somatic mosaicism: observations related to clinical genetics.
Hall, J. G. (1988) · Europe PMC (PubMed Central) · Cited by 342
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Phaneuf, D., Labelle, Y., Bérubé, D., Arden, K. C., Cavenee, W. K., Gagné, R., & Tanguay, R. M. (1991) · Europe PMC (PubMed Central) · Cited by 121
Tanguay, R. M., Valet, J. P., Lescault, A., Duband, J., Laberge, C. M., Lettre, F., & Plante, M. (1990) · Europe PMC (PubMed Central) · Cited by 105
Grenier, A., Lescault, A., Laberge, C., Gagné, R., & Marner, O. (1982) · Clinica Chimica Acta · doi:10.1016/0009-8981(82)90117-6 · Cited by 73
Kvittingen, E. A., Jellum, E., & Stokke, O. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90244-8 · Cited by 62
Self-citationTyrosinaemia type I — an update
Kvittingen, E. A. (1991) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01797926 · Cited by 58
Self-citationBiochemical studies on the enzymatic deficiencies in hereditary tyrosinemia
Berger, R., van Faassen, H., & Smith, G. P. A. (1983) · Clinica Chimica Acta · doi:10.1016/0009-8981(83)90191-2 · Cited by 45
Self-citationStoner, E., Starkman, H. S., Wellner, D., Wellner, V. P., Sassa, S., Rifkind, A. B., Grenier, A., Steinherz, P. G., Meister, A., New, M. I., et al. (1984) · Pediatric Research · doi:10.1203/00006450-198412000-00023 · Cited by 43
Research works printed but not linked: 1
- [1]1. Goldsmith, L. A., and C. Laberge. 1989. Tyrosinemia and related disorders. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. -S. Sly, and D. Valle, editors. McGraw-Hill Inc., New York 547–562.
Cited by
Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549
Mechanisms and consequences of somatic mosaicism in humans
Youssoufian, H., & Pyeritz, R. E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg906 · Cited by 391
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
“In older patients, the low production may in part be due to self-induced correction of the fumarylacetoacetase defect (Kvittingen et al 1993, 1994), which has been documented to occur in nodules of regenerative liver tissue.”
BackgroundMolecular Biology of Fanconi Anemia: Implications for Diagnosis and Therapy
D'Andrea, A. D., & Grompe, M. (1997) · Blood · doi:10.1182/blood.v90.5.1725 · Cited by 194
In Utero Hematopoietic Stem Cell Transplantation: Ontogenic Opportunities and Biologic Barriers
Flake, A. W., & Zanjani, E. D. (1999) · Blood · doi:10.1182/blood.v94.7.2179.419k43_2179_2191 · Cited by 190
Scott, C. R. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30092 · Cited by 186
“The children with the more chronic form of tyrosinemia-I, as manifest by chronic kidney disease, rickets, and growth failure, show a high incidence of allele reversion frommutant to normal in hepatic nodules [Kvittingen et al., 1993, 1994].”
BackgroundIn vivo reversion to normal of inherited mutations in humans
Hirschhorn, R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.10.721 · Cited by 182
“16 This type of mosaicism as to protein had been sporadically reported in different disorders, and primarily in studies of cells in culture.”
BackgroundHypermethioninemias of genetic and non‐genetic origin: A review
Mudd, S. H. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30293 · Cited by 181
“Liver samples from various areas contained fumarylacetoacetate activities ranging from 6 to 32 mmol/min in one patient and 0.4– 4mmol/min in another (control range 33–66 mmol/min) [Kvittingen et al., 1993].”
BackgroundInfluentialThe pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
“m sections of formalin-fixed liver tissue with an alkaline phosphatase/anti-alkaline phosphatase (APAAP) method as described previously (2).”
BackgroundMethodSelf-citationPrinciples of Therapeutic Liver Repopulation
Grompe, M., Laconi, E., & Shafritz, D. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007093 · Cited by 96
Kuivaniemi, H., Tromp, G., & Prockop, D. J. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:4<300::aid-humu2>3.0.co;2-9 · Cited by 372
Back mutation can produce phenotype reversion in Bloom syndrome somatic cells
Ellis, N. A., Ciocci, S., & GERMAN, J. L. (2001) · Human Genetics · doi:10.1007/s004390000447 · Cited by 133
“and in the non-hematopoietic compartment (e.g., Duchenne muscular dystrophy: Hoffman et al. 1990; Burrow et al. 1991; epidermolysis bullosa: Jonkman et al. 1997; tyrosinemia type I: Kvittingen et al. 1993 ).”
Chromosomal Integration of Adenoviral Vector DNA In Vivo
Stephen, S. L., Montini, E., Sivanandam, V. G., Al-Dhalimy, M., Kestler, H. A., Finegold, M. J., Grompe, M., & Kochanek, S. (2010) · Journal of Virology · doi:10.1128/jvi.00751-10 · Cited by 106
“Similar to human tyrosinemia type I patients with spontaneous reversions of point mutations (18), FAH-expressing hepatocytes have a strong growth advantage over FAH / hepatocytes, and the developing nodules, consisting of FAH-positive [FAH ] hepatocytes, can be easily distinguished in an environment of FAH / hepatocyt…”
BackgroundAdenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I
Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M., Tanguay, R., Lieber, A., Kay, M., & Grompe, M. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-513 · Cited by 77
“- ?, ficient cells (Kvittingen et al, 1993, 1994; Overturf et al, 1996). in Recently, we have shown that this phenomenon can be exploited to cortect > 9 0% of parenchymal hepatocytes of F AH mutant mice by rettovttal gene therapy (Overturf et al, 1996).”
Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1
Hickey, R. D., Mao, S. A., Glorioso, J., Elgilani, F., Amiot, B., Chen, H., Rinaldo, P., Marler, R., Jiang, H., DeGrado, T. R., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3838 · Cited by 75
“Similar to the mouse model (26) and as has been reported in humanHT1 patients (31), FAH cells had the proliferative advantage to expand and repopulate the Fah pig liver under selective NTBC withdrawal.”
ResultSomatic point mutations occurring early in development: a monozygotic twin study
Li, R., Montpetit, A., Rousseau, M., Wu, S. Y. M., Greenwood, C. M. T., Spector, T. D., Pollak, M., Polychronakos, C., & Richards, J. B. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101712 · Cited by 74
In Vivo Genetic Selection of Renal Proximal Tubules
Held, P. K., Al-Dhalimy, M., Willenbring, H., Akkari, Y. M. N., Jiang, S., Torimaru, Y., Olson, S. B., Fleming, W., Finegold, M. J., & Grompe, M. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.004 · Cited by 69
Demers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67
Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1
Morrow, G., & Tanguay, R. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_2 · Cited by 81
Tyrosine and its catabolites: from disease to cancer.
Tanguay, R. M., Jorquera, R., Poudrier, J., & St-Louis, M. (1996) · Acta Biochimica Polonica · doi:10.18388/abp.1996_4530 · Cited by 64
Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy.
Pasmooij, A. M. G., Jonkman, M. F., & Uitto, J. (2012) · PubMed · Cited by 74
Endo, F., Kubo, S., Awata, H., Kiwaki, K., Katoh, H., Kanegae, Y., Saito, I., Miyazaki, J.-I., Yamamoto, T., Jakobs, C., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24426 · Cited by 62
van Amstel, J. K. P., Bergman, A. J. I. W., van Beurden, E. A. C. M., Roijers, J. F. M., Peelen, T., van den Berg, I. E. T., Poll-The, B. T., Kvittingen, E. A., & Berger, R. (1996) · Human Genetics · doi:10.1007/bf00218833 · Cited by 60
“It has recently been reported that variable levels of FAH enzyme activity exist in liver tissue from HT 1 patients (Kvittingen et al. 1993).”
BackgroundSelf-citationPrinciples of therapeutic liver repopulation
Grompe, M. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0311-2 · Cited by 59
“Kvittingen and colleagues first showed that a similar phenomenon can also occur in human liver (Kvittingen et al 1993, 1994).”
BackgroundP450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity
Bissig, K., Han, W., Barzi, M., Kovalchuk, N., Ding, L., Fan, X., Pankowicz, F. P., Zhang, Q.-Y., & Ding, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083303 · Cited by 61
Liver repopulation for the treatment of metabolic diseases
Grompe, M. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1010375203539 · Cited by 56
“Spontaneous liver repopulation in HT I patients Recently an important observation was made in human patients with HT I. FAH immunostaining of livers removed at transplantation revealed the presence of a mosaic of antibody-positive and -negative hepatic tissue (Kvittingen et al 1993).”
BackgroundDifferent Clinical Forms of Hereditary Tyrosinemia (Type I) in Patients with Identical Genotypes
Poudrier, J., Lettre, F., Scriver, C. R., Larochelle, J., & Tanguay, R. M. (1998) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2695 · Cited by 63
In Utero Hematopoietic Stem Cell Transplantation: Progress toward Clinical Application
Merianos, D. J., Heaton, T. E., & Flake, A. W. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.012 · Cited by 54
“In these diseases there is presumably a survival advantage for the spontaneously corrected cells [100].”
BackgroundTherapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report
Grompe, M., Overturf, K., Al‐Dhalimy, M., & Finegold, M. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005462804271 · Cited by 54
In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
Manning, K., Al-Dhalimy, M., Finegold, M., & Grompe, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11928 · Cited by 51
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Stewart, D. M., Candotti, F., & Nelson, D. L. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9121-z · Cited by 50
“Other diseases with spontaneous genetic reversions include epidermolysis bullosa [15, 16], Fanconi anemia [17, 18], and hereditary tyrosinemia type I [19, 20].”
Background(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1098-1004(1998)12:1 · Cited by 1
Self-citationCell-based therapeutics for liver disorders
Vosough, M., Moslem, M., Pournasr, B., & Baharvand, H. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr031 · Cited by 44
MOLECULAR BIOLOGY OF FANCONI ANEMIA
Kupfer, G. M., Näf, D., & D’Andrea, A. D. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70482-2 · Cited by 44
Fah Knockout Animals as Models for Therapeutic Liver Repopulation
Grompe, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_20 · Cited by 46
Arranz, J. A., Piñol, F., Kozak, L., Pérez-Cerdá, C., Cormand, B., Ugarte, M., & Riudor, E. (2002) · Human Mutation · doi:10.1002/humu.10084 · Cited by 39
Hart, L. M. ‘., Jansen, J. J., Lemkes, H. H. P. J., de Knijff, P., & Maassen, J. A. (1996) · Human Mutation · doi:10.1002/(sici)1098-1004(1996)7:3<198::aid-humu3>3.0.co;2-7 · Cited by 105
Self-citationCassiman, D., Zeevaert, R., Holme, E., Kvittingen, E.-A., & Jaeken, J. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-28 · Cited by 38
“Liver enzyme activities and urinary and blood organic acid analysis Were performed as described previously [2,5].”
MethodSelf-citationIn Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral Vectors
Chen, S. J., Tazelaar, J., Moscioni, A. D., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0065 · Cited by 36
Hepatocellular carcinoma despite long‐term survival in chronic tyrosinaemia I
Kim, S. Z., Kupke, K. G., Ierardi-Curto, L. A., Holme, E., Greter, J., Tanguay, R. M., Poudrier, J., D’Astous, M., Lettre, F., Hahn, S. H., et al. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026756501669 · Cited by 40
“Kvittingen et al (1993, 1994) have shown that patients with chronic tyrosinaemia I may have a mosaic pattern of liver FAH with immunoreactive protein in some areas but immunonegativity and absence of enzyme activity in other areas.”
BackgroundPeroxisome mosaicism in the livers of peroxisomal deficiency patients
Espeel, M., Mandel, H., Poggi, F., Smeitink, J. A. M., Wanders, R. J. A., Kerckaert, I., Schutgens, R. B. H., Saudubray, J.-M., Poll-The, B.-T., & Roels, F. (1995) · Hepatology · doi:10.1002/hep.1840220219 · Cited by 35
Liver tumors in children with metabolic disorders.
Schady, D. A., Roy, A., & Finegold, M. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.10.08 · Cited by 39
“In cirrhotic livers of individuals with HT1, a remarkable phenomenon of genetic ‘reversion’ has been reported (27,28), in which rare discrete regenerative nodules are found to be immunoreactive for FAH protein interspersed with the vast majority of FAH-negative nodules.”
BackgroundRootwelt, H., Berger, R., Gray, G., Kelly, D. A., Coşkun, T., & Kvittingen, E. A. (1994) · PubMed Central · Cited by 37
Self-citationLiver Transplant Pathology in Pediatric Metabolic Disorders
Jaffe, R. (1998) · Pediatric and Developmental Pathology · doi:10.1007/s100249900013 · Cited by 31
Sauer, V., Siaj, R., Stöppeler, S., Bahde, R., Spiegel, H.-U., Köhler, G., Zibert, A., & Schmidt, H. (2011) · Liver Transplantation · doi:10.1002/lt.22466 · Cited by 37
“The selection of Fah-positive hepatocytes seems to be extraordinarily high and can occur in the livers of patients after a spontaneous mutational reversion of the Fah gene followed by clonal cell selection, which gives rise to Fah-positive nodules.(40) However, such spontaneous selection does not reverse hereditary ty…”
BackgroundDisorders of phenylalanine and tyrosine metabolism
Alsharhan, H., & Ficicioglu, C. H. (2020) · Translational Science of Rare Diseases · doi:10.3233/trd-200049 · Cited by 45
“As is typical, multiple large and small nodules were found [138]; however, an immunohistological analysis with FAH antibody surprisingly, showed that the livers represented a mosaic of antibody positive and negative hepatic tissue.”
BackgroundTyrosinaemia type I—de novo mutation in liver tissue suppressing an inborn splicing defect
Bliksrud, Y. T., Brodtkorb, E., Andresen, P. A., van den Berg, I. E. T., & Kvittingen, E. A. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0648-2 · Cited by 33
“Most sections were stained with an alkaline phosphatase/ anti-alkaline phosphatase method as described previously [6].”
MethodSelf-citationStem cell and genetic therapies for the fetus
Flake, A. W. (2003) · Seminars in Pediatric Surgery · doi:10.1016/s1055-8586(03)00024-6 · Cited by 26
Round two for liver gene therapy
Wilson, J. M. (1996) · Nature Genetics · doi:10.1038/ng0396-232 · Cited by 24
Rootwelt, H., Kristensen, T., Berger, R., H�ie, K., & Kvittingen, E. (1994) · Human Genetics · doi:10.1007/bf00208276 · Cited by 23
“Recently, we showed that some HT1 patients had a mosaic pattern of immunoreactive FAH protein and enzyme activity in liver tissue ( Kvittingen et al. 1993 ).”
BackgroundSelf-citationRootwelt, H., Chou, J., Gahl, W. A., Berger, R., Coşkun, T., Brodtkorb, E., & Kvittingen, E. A. (1994) · Human Genetics · doi:10.1007/bf00201558 · Cited by 23
“The three Norwegian patients have evidence of a mosaic pattern of FAH activity in liver tissue, as recently described for five other Norwegian patients with chronic HT1 (Kvittingen et al. 1993).”
BackgroundSelf-citationFetal hematopoietic stem cell transplantation
Shaaban, A. F., & Flake, A. W. (1999) · Seminars in Perinatology · doi:10.1016/s0146-0005(99)80030-5 · Cited by 22
Chen, S., Tazelaar, J., & Wilson, J. M. (2001) · Human Gene Therapy · doi:10.1089/104303401450951 · Cited by 22
“Analysis of hepatic tissue from these patients after liver transplantation demonstrated clonal expansion of spontaneously reverted hepatocytes (Kvittingen et al ., 1993, 1994).”
Molecular Aspects of the FAH Mutations Involved in HT1 Disease
Morrow, G., Angileri, F., & Tanguay, R. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_3 · Cited by 22
Hereditary tyrosinaemia type I: from basics to progress in treatment
Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2000) · Annals of Medicine · doi:10.3109/07853890008998832 · Cited by 21
van den Akker, P. C., Pasmooij, A. M. G., Joenje, H., Hofstra, R. M. W., Meerman, G. J. T., & Jonkman, M. F. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192994 · Cited by 19
Paulk, N. K., Wursthorn, K., Haft, A., Pelz, C., Clarke, G. N., Newell, A. H., Olson, S. B., Harding, C. O., Finegold, M. J., Bateman, R. L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.154 · Cited by 19
'Identical' twins with discordant karyotypes
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0223(199901)19:1 · Cited by 1
Zytkovicz, T. H., Sahai, I., Rush, A., Odewale, A., Johnson, D. M., Fitzgerald, E. F., Britton, D., & Eaton, R. B. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.02.002 · Cited by 16
Hepatic Neoplasia and Metabolic Diseases in Children
Roy, A., & Finegold, M. J. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.07.002 · Cited by 16
Contemporary Evaluation of the Pediatric Liver Biopsy
Schady, D. A., & Finegold, M. J. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.01.013 · Cited by 18
Dijkstra, A. M., van Vliet, K., Heiner-Fokkema, M. R., Bodewes, F. A. J. A., Bos, D. K., Zsíros, J., van Aerde, K., Koop, K., van Spronsen, F. J., & Lubout, C. M. A. (2023) · International Journal of Neonatal Screening · doi:10.3390/ijns9040066 · Cited by 14
“These phenotypes can be the result of a gene reversion, meaning spontaneous self-correction of the germline pathogenic FAH variant with partial restoration of hepatocyte FAH activity [19,22,25].”
BackgroundLiver disease and compensatory growth: unexpected lessons from genetically altered mice
Braun, K. M., & Sandgren, E. P. (1998) · The International Journal of Developmental Biology · doi:10.1387/ijdb.9853824 · Cited by 14
Somatic mosaicism for PDHA1 mutation in a male with pyruvate dehydrogenase complex deficiency
Coughlin, C. R., Krantz, I. D., Schmitt, E. S., Zhang, S., Wong, L.-J. C., Kerr, D. S., & Ganesh, J. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.04.004 · Cited by 13
Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your Eyes
van den Akker, P. C., Bolling, M. C., & Pasmooij, A. M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092118 · Cited by 13
Junge, N., Yuan, Q., Vu, T. H., Krooss, S. A., Bednarski, C., Balakrishnan, A., Cathomen, T., Manns, M. P., Baumann, U., Sharma, A. D., et al. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i2.277 · Cited by 12
Genetic Therapies for the Fetus
Flake, A. W. (2002) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200209000-00012 · Cited by 12
“In these diseases there is presumably a survival advantage for the spontaneously corrected cells.(45) Such correction has been noted in ADA SCID,(46) Fanconi anemia,(47) and Bloom’s syndrome,(48) the latter two of which are chromosomal breakage syndromes.”
BackgroundNguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 13
Rodent Models of Liver Repopulation
Gilgenkrantz, H. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-688-7_26 · Cited by 12
In utero transplantation of haemopoietic stem cells
Flake, A. W. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0166 · Cited by 10
Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1
Park, H., Lee, D. H., Choi, T.-Y., Lee, Y. K., Kim, J., Ki, C., & Lee, Y.-W. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.223 · Cited by 12
“There are variable levels of FAH enzyme activity in liver tissue from patients with HT1 (8).”
BackgroundNo evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients
Bergeron, A., Lettre, F., Russo, P., Morissette, J., & Tanguay, R. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.013 · Cited by 10
Dehghani, S. M., Haghighat, M., Imanieh, M. H., Karamnejad, H., & Malekpour, A. (2013) · PubMed Central · Cited by 14
Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine
Álvarez, F., & Mitchell, G. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_5 · Cited by 9
Hahn, S. H., Krasnewich, D. M., Brantly, M., Kvittingen, E. A., & Gahl, W. A. (1995) · Human Mutation · doi:10.1002/humu.1380060113 · Cited by 10
Self-citationGenome editing in the human liver: Progress and translational considerations
Ginn, S. L., Christina, S., & Alexander, I. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.030 · Cited by 8
La tyrosinémie héréditaire : une maladie du stress du réticulum endoplasmique ?
Bergeron, A., Jorquera, R., & Tanguay, R. M. (2003) · médecine/sciences · doi:10.1051/medsci/20031910976 · Cited by 10
“La fréquence élevée (37%) de cancer du foie chez les patients TH1 agés de plus de deux ans [13] ainsi que l’observation d’un pourcentage élevé de réversion de mutation dans le gène fah dans le foie [7-9], suggèrent qu’un produit de dégradation de la tyrosine puisse causer des dommages à l’ADN.”
Russo, R. S., & Wilcox, W. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00003-0 · Cited by 6
Morrow, G., Dreumont, N., Bourrelle-Langlois, M., Roy, V., & Tanguay, R. M. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.01.019 · Cited by 4
Tanguay, R. M., Bergeron, A., & Jorquera, R. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-449851-8.00040-1 · Cited by 5
Flake, A. W., & Zanjani, E. D. (2003) · doi:10.1002/9780470987070.ch44 · Cited by 3
Stewart, D. M., Candotti, F., & Nelson, D. L. (2007) · Cited by 2
Mitchell, G. A., Russo, P., Dubois, J., & Álvarez, F. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139012102.032 · Cited by 2
Wang, R., Wilcox, W. R., & Cederbaum, S. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00096-3 · Cited by 11
Thrust and parry of hepatocytes regains respect on the liver regeneration front
Gupta, S. K. (1998) · Hepatology · doi:10.1002/hep.510270436 · Cited by 1
Hepatorenal tyrosinemia/fumarylacetoacetate hydrolase deficiency
Nyhan, W., Barshop, B. A., & Ozand, P. (2005) · CRC Press eBooks · doi:10.1201/b13565-32 · Cited by 1
Hepatorenal tyrosinemia/fumarylacetoacetate hydrolase deficiency
Nyhan, W., Hoffmann, G. F., Barshop, B. A., & Al-Aqeel, A. (2011) · CRC Press eBooks · doi:10.1201/b13564-24 · Cited by 1
Rodeck, B., & Baumann, U. (2004) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-004-1026-9 · Cited by 2
“In explantierten Lebern fand man mit immunhistologischen Methoden (FAH-Antikörpern) Areale mit positiver Reaktion neben Arealen mit negativer Reaktion [28].”
BackgroundChromosomal integration in vitro and in vivo of high capacity adenoviral vectors
Stephen, S. L. (2007) · Kölner Universitäts PublikationsServer (Universität zu Köln)
une maladie du stress endoplasmique
Bergeron, A., Jorquera, R., & Tanguay, R. M. (2003)
Abnormalities of Hepatic Protein Metabolism
A‐Kader, H. H., & Ghishan, F. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0774-8.10072-7 · Cited by 1
An assessment of genomic sequence restoration in Arabidopsis thaliana
Khalid, A. M. (2009) · UWSpace (University of Waterloo)
Step by step diagnosis of hereditary tyrosinemia type I in children
Namazova-Baranova, L. S., Васильевна, В. Г., Nikitin, A. V., Андреевна, С. Т., Сергеевна, К. А., Smirnov, I. E., Bushueva, T. V., Konova, S. R., Ильин, А., Курбатова, О. В., et al. (2019) · Russian Pediatric Journal · doi:10.18821/1560-9561-2016-19-3-132-137
Mitchell, G. A., Russo, P., Dubois, J., Halac, U., & Álvarez, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108918978.031 · Cited by 1
Abnormalities of Hepatic Protein Metabolism
A‐Kader, H. H., & Ghishan, F. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00072-4
Mitchell, G. A., Russo, P., Dubois, J., & Álvarez, F. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.031 · Cited by 2
Metadata
- Authors
- Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R.
- Affiliations
- University of Oslo (NO)
- Oslo University Hospital (NO)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-04-01
- Volume
- 91
- Issue
- 4
- Pages
- 1816-1821
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC288163
- OpenAlex
- W2162704354
- Cited by
- 102
- References
- 20
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- tyrosinemia type I, liver transplantation, residual enzyme activity, enzyme induction, mosaicism, immunohistochemistry, liver regeneration, enzyme stability, mRNA translation
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Child, Child, Preschool, Family Health, Fibroblasts, Humans, Hydrolases, Immunohistochemistry, Infant, Liver, Norway, Subcellular Fractions, Tyrosine, Blotting, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.